

# Calogero Camma'

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6809204/publications.pdf>

Version: 2024-02-01

19  
papers

879  
citations

623188

14  
h-index

887659

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1692  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. Alimentary Pharmacology and Therapeutics, 2017, 46, 617-627.	1.9	134
2	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Alimentary Pharmacology and Therapeutics, 2017, 46, 688-695.	1.9	124
3	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	3.6	97
4	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology, 2013, 57, 1046-1054.	3.6	89
5	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2014, 59, 1692-1705.	3.6	75
6	A meta-analysis of single <sc>HCV</sc>-untreated arm of studies evaluating outcomes after curative treatments of <sc>HCV</sc>-related hepatocellular carcinoma. Liver International, 2017, 37, 1157-1166.	1.9	70
7	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	6.1	62
8	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver International, 2017, 37, 1389-1396.	1.9	44
9	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis. Digestive and Liver Disease, 2015, 47, 324-330.	0.4	43
10	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2013, 59, 658-666.	1.8	41
11	Usefulness of the index of <sc>NASH</sc> " <sc>ION</sc> for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver International, 2018, 38, 715-723.	1.9	22
12	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. Liver International, 2018, 38, 2108-2116.	1.9	20
13	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Alimentary Pharmacology and Therapeutics, 2022, 55, 604-615.	1.9	18
14	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2014, 46, 936-942.	0.4	17
15	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. Liver International, 2021, 41, 1105-1116.	1.9	10
16	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	1.9	6
17	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. Liver International, 2021, 41, 2179-2188.	1.9	3
18	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International, 0, , .	0.2	3

#	ARTICLE	IF	CITATIONS
19	Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation – authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 862-863.	1.9	1